Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Elizabeth Weil"'
Cutaneous Metastasis due to Breast Cancer in a Patient with Primary Biliary Cirrhosis: A Case Report
Publikováno v:
Case Reports in Oncology, Vol 9, Iss 3, Pp 718-725 (2016)
Background: Breast cancer is the most common solid tumor to cause cutaneous metastases. These are incurable and the treatment goal is geared toward local control with surgical excision, radiation, and chemotherapy. However, treatment can be challengi
Externí odkaz:
https://doaj.org/article/5d0fdc7765cb4d2bbbf99651f2559808
Autor:
Heun Min, Elizabeth Weil, Maggie Nelson, John Charlson, Meghan Conroy, Miracle Powell, Yee Chung Cheng, Lubna N. Chaudhary, John Burfeind, Janet Retseck, Deepika Sriram, Sailaja Kamaraju
Publikováno v:
Cancer Research. 83:P5-07
Introduction: Breast cancer patients with intracranial (IC) metastases including leptomeningeal metastasis (LM) confer poor prognosis. Upon disease progression with standard lines of therapy, high-dose intravenous methotrexate (HD IV MTX) is offered
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b13b242118fa1fa6c0db93ed2fece949
https://doi.org/10.1158/1538-7445.sabcs22-p5-07-05
https://doi.org/10.1158/1538-7445.sabcs22-p5-07-05
Autor:
Lubna Naaz Chaudhary, Julie Jorns, Yunguang Sun, Yee Chung Cheng, Sailaja Kamaraju, John Burfeind, MaryBeth Gonyo, Amanda Kong, Caitlin Patten, Tina Yen, Chandler Cortina, Ebony Carson, Nedra Johnson, Carmen Bergom, Shirng-Wern Tsaih, Anjishnu Banerjee, Yu Wang, Inna Chervoneva, Elizabeth Weil, Christopher R Chitambar, Hallgeir Rui
Background. Endocrine resistant metastatic disease develops in ~20-25% of hormone-receptor positive (HR+) breast cancer (BC) patients despite endocrine therapy (ET) use. Upregulation of HER family receptor tyrosine kinases (RTKs) represent escape mec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::248a572849afe55c1fb5987de5c5fd37
https://doi.org/10.21203/rs.3.rs-2777910/v1
https://doi.org/10.21203/rs.3.rs-2777910/v1
Autor:
Meghan Conroy, Miracle Powell, Sneha Nagavally, Aprill Dawson, Anna Beckius, Heun Min, Maressa Sweeney, Elizabeth Weil, Angela Hallbach, Lubna N. Chaudhary, Yee Chung Cheng, Jutta Deiinger, John Burfeind, Janet Retseck, Tamiah Wright, John Charlson, Sailaja Kamaraju
Publikováno v:
Cancer Research. 83:P6-05
Introduction: Despite evidence that utilization of Electronic Medical Record (EMR) messaging positively impacts patients with cancer, there is little research on who uses EMR messaging and for what purpose. Methods: Sociodemographic and MyChart usage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0e6e74ac6bbc87b74a14dc1ad59ec1a
https://doi.org/10.1158/1538-7445.sabcs22-p6-05-52
https://doi.org/10.1158/1538-7445.sabcs22-p6-05-52
Autor:
Joan Neuner, Elizabeth Weil, Nicole Fergestrom, Melinda Stolley, Sailaja Kamaraju, Carolyn Oxencis, Aaron Winn, Purushottam W. Laud, Kathryn E. Flynn
Publikováno v:
Journal of the American Pharmacists Association. 62:1321-1328.e3
Adjuvant endocrine therapy (AET) for breast cancer reduces mortality, but one-third to one-half of patients discontinue it early or are nonadherent.We developed a pilot single-site study of patients with evidence of early nonadherence to AET to asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6caefcdbd9806b1d12d9b853d6ea71df
https://doi.org/10.1016/j.japh.2022.03.001
https://doi.org/10.1016/j.japh.2022.03.001
Autor:
Carol A. Lange, Yee Chung Cheng, Hallgeir Rui, Christopher R. Chitambar, Lubna N Chaudhary, Martin Lehr, Douglas Yee, Amy M. Fowler, Thu H. Truong, Kari B. Wisinski, Sailaja Kamaraju, Elizabeth Weil
Publikováno v:
Endocrinology. 162
Although incurable, the prognosis for patients with metastatic breast cancer (MBC) has considerably improved with the approvals of multiple targeted and cytotoxic therapies. For hormone receptor-positive (HR+), ie, estrogen receptor and progesterone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3197466efa7f4102ecbc491944d45bc6
https://doi.org/10.1210/endocr/bqab060
https://doi.org/10.1210/endocr/bqab060
Autor:
Nicole Fergestrom, Sailaja Kamaraju, Kathryn E. Flynn, Stolley M, Aaron N. Winn, Oxencis C, Joan M. Neuner, Prakash Laud, Elizabeth Weil
Background Adjuvant endocrine therapy (AET) for breast cancer reduces mortality, but one-third to one-half of patients discontinue it early or are nonadherent. We developed a pilot single-site study of patients with evidence of early nonadherence to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39f8f3391d4c3a02ebd97ed4370eb8ab
https://doi.org/10.21203/rs.3.rs-249542/v1
https://doi.org/10.21203/rs.3.rs-249542/v1
Autor:
Svetlana Zaharova, Joseph McGraw, John Tierney, Olubadewa Fatunde, James Lokken, Meera Mohan, Elizabeth Weil, Sherry-Ann Brown, Brianna Wallace, Sailaja Kamaraju
Publikováno v:
Clin Sci (Lond)
Recent advances in treatment have transformed the management of cancer. Despite these advances, cardiovascular disease remains a leading cause of death in cancer survivors. Cardio-oncology has recently evolved as a subspecialty to prevent, diagnose,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::399f8213429c816205250f45c58f594a
https://pubmed.ncbi.nlm.nih.gov/34076246
https://pubmed.ncbi.nlm.nih.gov/34076246
Autor:
Rachel E. Goodman, Sarah Elizabeth Thordsen, Nithya Sridhar, Anna Calderon, Elizabeth Weil, Lubna N. Chaudhary, Sailiaja Kamaraju, Janet Retseck, John Charlson, John Burfeind, Christopher R. Chitambar, Yee Chung Cheng, Sherry-Ann Brown
Publikováno v:
Journal of the American College of Cardiology. 79:1887
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4a8e71e86073ea3c1bd8a0110f91b52
https://doi.org/10.1016/s0735-1097(22)02878-9
https://doi.org/10.1016/s0735-1097(22)02878-9
Autor:
Sailaja Kamaraju, Joan M. Neuner, Elizabeth Weil, Andrew J Ernst, Kathryn E. Flynn, Nicole Fergestrom, Bradley H. Crotty
Publikováno v:
Clin Breast Cancer
Purpose Aromatase inhibitor (AI) associated symptoms are large contributors to early discontinuation. Though guidelines exist for management of these symptoms, little is known about the degree to which physicians address symptoms and adhere to the gu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af2469cc051aa501fa46fdc36dc340c8
https://pubmed.ncbi.nlm.nih.gov/33183969
https://pubmed.ncbi.nlm.nih.gov/33183969